Sobi pursues the transformation of R&D

0

STOCKHOLM, December 13, 2021 / PRNewswire / – Anders Ullman, MD, Ph.D., currently a member of the Board of Directors of Sobi, will become Head of R&D and Chief Medical Officer and will replace Ravi Rao, MD, Ph.D. Dr Ullman brings extensive experience and knowledge of the global pharmaceutical industry, having previously led R&D organizations and change processes at other companies including Bayer, Nycomed and Baxter. To support the transformation, Dr Ullman will be based at Basel, Switzerland, report to the CEO Guido Oelkers and become a member of the executive committee of Sobi.

Guido Oelkers: “We welcome Anders to his new role, having served in 2021 on the board of directors of Sobi. Anders has extensive experience in the pharmaceutical industry including rare disease knowledge of at least two companies and the late stage development of a number of drugs and will be a great addition to the team here.

We would also like to thank Ravi for his contributions over the past years and wish him the best in his future endeavors. From his early days at Sobi, Ravi has initiated a transformation of both the R&D pipeline and the organization with a focus on lifecycle teams leading the development of our important medicines and our innovative pipeline that will serve well. Sobi in the future. “

The change in R&D direction is expected to be fully implemented in early 2022 following a handover process that will begin by now. mid-December 2021. Dr Ullman will be stepping down from Sobi’s Board of Directors following the leadership appointment.

With a main presence in R&D in Stockholm, Sweden and Basel, Switzerland and satellite R&D offices in Durham, North Carolina, United States and Tokyo, Japan, Sobi R&D employs approximately 220 colleagues in functions spanning bioanalysis and biostatistics, translational science, clinical science and late stage program development, clinical operations, medical writing, regulatory affairs, pharmacovigilance and Portfolio Management. More information on the Sobi pipeline here.

Anders Ullman

Born in 1956, Dr Ullman trained as a doctor in Sweden before obtaining a doctorate. in clinical pharmacology and board certification. In 1990, Dr Ullman joined the pharmaceutical industry where he held positions of increasing responsibility at Upjohn, Astra, AstraZeneca, Bayer, Biovitrum, a predecessor of Sobi, Nycomed, Takeda and Baxter. In 2015, Dr Ullman returned to academia to head a pulmonology unit at Sahlgrenska University Hospital in Gothenburg, Sweden. External director mandates include Verona Pharma and Sobi with previous mandates at NeuroSearch and PExA. More information on Anders Ullman here.

Contacts
To find out how to contact Sobi’s Investor Relations team, click here. For Sobi Media contacts, click here.

Sobi
Sobi is an international biopharmaceutical company specializing in transforming the lives of people with rare diseases. Sobi offers sustainable access to innovative drugs in the fields of hematology, immunology and specialized care. Sobi employs around 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi’s turnover amounts to SEK 15.3 billion. Sobi (STO: SOBI) shares are listed on Nasdaq Stockholm. Learn more about Sobi on sobi.com, LinkedIn and YouTube.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-continues-the-rd-transformation-anders-ullman-appointed-new-head-of-rd,c3470663

The following files are available for download:


Source link

Share.

Comments are closed.